- Details
- Drs Charles Ryan and Alicia Morgans discuss the approval of Pluvicto TM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617). Pluvicto was approved based on the pivotal Phase III VISION trial which evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined...
|
- Details
- Alicia Morgans converses with Scott Tagawa about patient-reported outcomes in men undergoing PSMA targeted radiopharmaceutical treatments for prostate cancer. The discussion centers on a Department of Defense-funded study that aims to develop a new patient-reported outcome tool specifically for this patient population. Dr. Tagawa elaborates on the instruments commonly used in clinical trials, such...
|
- Details
- Alicia Morgans with Arun Azad and Declan Murphy about an ongoing clinical trial exploring the use of Lutetium PSMA for treating newly diagnosed metastatic hormone-sensitive prostate cancer. Dr. Azad reveals that the trial aims to assess whether adding Lutetium PSMA to standard chemo-hormonal therapy improves efficacy. The study has garnered significant interest, enrolling over a quarter of its tar...
|
- Details
- Bennett Chin discusses Lutetium-177 PSMA, an investigational class of targeted, radionuclide agents. The focus of this treatment is on Prostate-Specific Membrane Antigen (PSMA), a molecule overexpressed on higher-grade prostate cancer cells. Lutetium-177 is a radioactive beta emitter that binds to PSMA, delivering highly targeted radiation therapy to prostate cancer cells. This emitter also has mi...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 1 15 minutes: Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Presented by Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS 20 minutes: Discussion Moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Professor Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 2 12 minutes: PSMA-PET Diagnostic Imaging in Prostate Cancer - Presented by Thomas Hope, MD Module 3 16 minutes: PSMA as a Therapeutic Target in Progressing Prostate Cancer - Presented by Johannes Czernin, MD 22 minutes: Discussion moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Joh...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 4 10 minutes: Treatment considerations following 177Lu-PSMA - Presented by Scott Tagawa, MD, MS, FACP 17 minutes: PSMA Imaging: A Necessary Gateway for PSMA-Directed Therapy? - Presented by Michael Morris, MD 24 minutes: Discussion Moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Sco...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer. Module 5 12 minutes: PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Introducing the Pivotal Phase III VISION Trial - Presented by Oliver Sartor, MD 11 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biographies: Oliver Sartor, M.D. C.E. and Bernadine Laborde Professor of...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 6 14 minutes: Precision Medicine: RadioIsotopes Targeted Therapies in Cancer - Presented by Stefano Fanti, MD 15 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Stefano Fanti, MD Nuclear Medicine Physician, Director of the Nuclear Medicine Division and PET Uni...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 7 9 minutes: Academic Practice Perspectives on Integrating PSMA Lu-177 into Clinical Practice: Lessons Learned from Radium-223 and More - Presented by Oliver Sartor, MD. 6 minutes: Practice Patterns in a Community Medical Oncology Applied to Lutetium: Parallels between lutetium and operationalizing radium-223 - Presented by N...
|
